Search company, investor...

Founded Year




Date of IPO


Market Cap


Stock Price


About Singular Genomics

Singular Genomics (NASDAQ: OMIC) develops next-generation sequencing and multi-omics technologies. It helps to build products that empower researchers and clinicians. The company was founded in 2016 and is based in San Diego, California.

Headquarters Location

3010 Science Park Road Suite 100

San Diego, California, 92121,

United States


Singular Genomics's Products & Differentiators

    G4 Integrated Solution

    The G4 Instrument is a benchtop next-generation sequencer designed to produce fast and accurate genetic sequencing results for specific targeted applications, including rare variant detection with high definition and synthetic long read (SLR) sequencing, which can be applied in rapidly growing markets such as oncology, including liquid biopsy detection of cell-free DNA, and immune response profiling to help researchers better harness the immune system in fighting infectious diseases, autoimmune disorders and immunotherapies for cancer.


Singular Genomics Patents

Singular Genomics has filed 113 patents.

The 3 most popular patent topics include:

  • molecular biology
  • biotechnology
  • dna
patents chart

Application Date

Grant Date


Related Topics





Application Date


Grant Date



Related Topics



Latest Singular Genomics News

Singular Genomics Reports Recent Highlights and Third Quarter 2023 Financial Results

Nov 14, 2023

Singular Genomics Reports Recent Highlights and Third Quarter 2023 Financial Results November 14, 2023 at 04:02 pm EST Share SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2023. “We shipped five G4 systems in the third quarter, our highest quarterly total yet, launched Max Read flow cell kits for single cell sequencing, and saw our largest number of quarterly consumable kit orders,” said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. “In the near term, we will be building our installed base more aggressively and prioritizing fewer yet higher impact products on our product roadmap. We have also cut costs to extend runway, providing time to build our installed base, get high-impact products to market, and scale revenue.” Third Quarter and Recent Highlights Generated revenue of $0.5 million in the third quarter of 2023. Shipped five G4 systems in the third quarter of 2023, increasing the total number of commercial systems shipped to 16 as of the end of the third quarter of 2023. Converted the majority of the installed base to F3 flow cells, allowing users to get up to 450 million reads per flow cell, or 1.8 billion reads per run, for some of the most widely run applications. Completed the early access program and commenced the broad commercial launch of Max Read flow cell kits for single cell sequencing, enabling 800 million reads per flow cell, or 3.2 billion reads per run. Implemented cost-cutting measures, including a workforce reduction of approximately 10%, to reduce operating expenses and extend cash runway into the first quarter of 2026. Third Quarter 2023 Financial Results Revenue for the third quarter of 2023 was $0.5 million, driven primarily by recognition of sales on one instrument placement. The company expects revenue from the remaining four instrument shipments to be recognized over time as customers purchase consumables for these instruments. Operating expenses for the third quarter of 2023 totaled $24.5 million, compared to $24.7 million for the third quarter of 2022. Operating expenses included non-cash stock-based compensation of $2.8 million for the third quarter of 2023 and $3.4 million for the third quarter of 2022. The year over year decrease in total operating expenses was driven primarily by a decrease in research and development materials and other general lab supply costs as the company transitioned from development to commercialization of the G4. Net loss for the third quarter of 2023 was $22.4 million, or a loss of $0.31 per common share, compared to $23.8 million, or a loss of $0.33 per common share, for the third quarter of 2022. Cash, cash equivalents and short-term investments, excluding restricted cash, totaled $190.7 million as of September 30, 2023. Webcast and Conference Call Details Singular Genomics’ management team will host a conference call today, November 14, 2023, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing 1-888-506-0062 for domestic callers or 1-973-528-0011 for international callers and using conference ID 616134 approximately five minutes prior to the start time. A live and archived webcast of the event will be available at, in the Presentations & Events section. About Singular Genomics Systems, Inc. Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4 Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In addition, Singular Genomics commenced development of the PX system, which leverages Singular’s proprietary sequencing technology, applying it as an in situ readout to look at RNA and proteins in single cells and tissue. Singular Genomics’ mission is to empower researchers and clinicians to advance science and medicine. Visit for more information. Forward-Looking Statements Certain statements contained in this press release, other than historical information, constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding: (i) our ability to successfully manufacture, commercialize and support the G4 and our flow cell kits in accordance with our timelines, objectives and specifications; (ii) our ability to ship Max Read kits to our broader customer base on our timeline; (iii) our expectations on cash runway, including whether our cost-cutting measures will have any material impact on our operating expenses or cash runway; (iv) our expectations regarding future revenue; and (v) quotes of management. Any such forward-looking statements are based on our management’s current expectations and are subject to risks and uncertainties that could cause our actual future results to differ materially from our management’s current expectations or those implied by our forward-looking statements. These risks and uncertainties include, but are not limited to, the following: (i) we have incurred significant losses since inception, we expect to incur significant losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability; (ii) we have very little history manufacturing and commercializing our products or technology; (iii) the life sciences technology market is highly competitive, and if we fail to compete effectively, our business and operating results will suffer; (iv) if we are sued for infringing, misappropriating or otherwise violating intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our products; (v) if our products fail to achieve early customer and scientific acceptance, we may not be able to achieve broader market acceptance for our products, and our revenues and prospects may be harmed; (vi) we expect to be highly dependent upon revenue generated from the sale of the G4 and future products, and any delay or failure by us to successfully manufacture and commercialize the G4 and future products could have a substantial adverse effect on our business and results of operations; and (vii) recent macroeconomic challenges such as inflation and rising interest rates may materially and adversely impact our business, operations, product manufacturing and commercialization objectives. These and other risk factors that may affect our future results of operations are identified and described in more detail in our most recent filings on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time, including our Quarterly Report on Form 10-Q for the period ended September 30, 2023, filed with the SEC on November 14, 2023. Accordingly, you should not rely on forward-looking statements as predictions of future events or our future performance. Except as required by law, we undertake no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Investor Contact

Singular Genomics Frequently Asked Questions (FAQ)

  • When was Singular Genomics founded?

    Singular Genomics was founded in 2016.

  • Where is Singular Genomics's headquarters?

    Singular Genomics's headquarters is located at 3010 Science Park Road, San Diego.

  • What is Singular Genomics's latest funding round?

    Singular Genomics's latest funding round is IPO.

  • Who are the investors of Singular Genomics?

    Investors of Singular Genomics include ARCH Venture Partners and F-Prime Capital.

  • Who are Singular Genomics's competitors?

    Competitors of Singular Genomics include 10X Genomics and 2 more.

  • What products does Singular Genomics offer?

    Singular Genomics's products include G4 Integrated Solution and 1 more.

  • Who are Singular Genomics's customers?

    Customers of Singular Genomics include Sanford Burnham and Fate Therapeutics.


Compare Singular Genomics to Competitors

Algorithmic Biologics

Algorithmic Biologic offers molecular discovery and diagnostics solutions. Its first product, Tapestry, is a regulatory-approved, algorithmic solution to provide large-scale COVID-19 testing. The company was founded in 2021 and is based in Bangalore, India.

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company focused on providing business intelligence in the pharmaceutical and biologic drugs sector. The company's main services include offering insights on life cycle management, brand erosion, generic entry, biosimilars, patents, sales, litigation, and more, all related to pharmaceutical and biologic drugs. The company primarily serves the biopharmaceutical industry. It is based in Troy, New York.


Sequentify is a company focused on genomics within the biotechnology industry. It offers novel library-prep solutions for Next-Generation Sequencing, developing sample processing technologies that drastically reduce cost and time. The company primarily serves the healthcare and personalized medicine sectors. It was founded in 2021 and is based in Rehovot, Israel.

DeepTrait Logo

DeepTrait focuses on the development of instruments for the analysis of the human genome with the use of artificial intelligence.

Singleron Biotechnologies Logo
Singleron Biotechnologies

Singleron Biotechnologies is a biotech company. The company focuses on applying single-cell analysis technologies in the healthcare sector. The company offers a comprehensive solution for single-cell multi-omics sequencing, which allows for novel approaches in clinical research and molecular diagnostics. The company primarily serves the healthcare industry, particularly in areas of clinical diagnosis, drug development, and health management. It was founded in 2018 and is based in Cologne, Germany.

SeekGene Logo

SeekGene specializes in single-cell sequencing and TCR-pMHC pairing technologies in understanding immune responses in the single-cell resolution to help screen, treat and monitor diseases.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.